Lecrolin eye drops 40 mg/ml. 5 ml. vial №1

$12.00

Manufacturer: Finland

Acute and chronic allergic conjunctivitis.

Category:

Description

Lecrolin Storage
active substances: sodium cromoglycate;

1 ml of eye drops contains 40 mg of sodium cromoglycate;

Excipients: glycerin, edetate disodium, polyvinyl alcohol, benzalkonium chloride, water for injections.

Lecrolin Dosage form
Eye drops.

Main physical and chemical properties: clear, colorless or slightly yellowish solution.

Does not contain visible particles.

Lecrolin Pharmacotherapeutic group
Means used in ophthalmology. Anti-edema and anti-allergic drugs. Other antiallergic drugs. ATC code S01G X01.

Lecrolin Pharmacological properties

Pharmacodynamics

Sodium cromoglycate inhibits mast cell degranulation by stabilizing the cell membrane, thus preventing the release of histamine and other inflammatory substances. Given the mechanism of action of the drug, the greatest effect is achieved if the drops are also used for prophylactic purposes. The use of Lecrolin® eye drops reduces the need for steroids and antihistamines for the treatment of allergic conjunctivitis. This medicine does not prevent bacterial or viral conjunctivitis.

Pharmacokinetics

Sodium cromoglycate is reversibly bound to plasma proteins, approximately 65%.

The absorption of sodium cromoglycate into the eye and blood is negligible. Bioavailability in humans after instillation into the eye is 0.03%. Sodium cromoglycate is not metabolized, but excreted unchanged in bile and urine. After parenteral administration, the plasma half-life is approximately 80 minutes.

Indication
Acute and chronic allergic conjunctivitis.

Contraindication
Hypersensitivity to sodium cromoglycate, benzalkonium chloride or to other components of the drug.

Interaction with other medicinal products and other forms of interaction
At simultaneous use of drug with other local ophthalmic means it is necessary to maintain a 15-minute interval between instillations.

Sodium cromoglycate has no adverse interactions.

Features of application
Lecrolin® contains benzalkonium chloride as a preservative, which may cause eye irritation. Benzalkonium chloride can be deposited in soft contact lenses and discolored. Before instilling the lenses should be removed and wait at least 15 minutes before putting them on again.

As with any eye drop, the use of Lecrolin® can lead to transient visual disturbances.

When instilling eye drops, avoid any contact of the dropper tip with the eye or skin.

In general, contact lenses are not recommended for allergic conjunctivitis.

Use during pregnancy and breastfeeding

No side effects in the fetus when used during pregnancy. However, it is recommended to use the drug during pregnancy when the expected effect of therapy for women exceeds the potential risk to the fetus.

Sodium cromoglycate may pass into breast milk, but no adverse effects on the infant have been reported at the recommended doses.

Ability to influence the speed of reaction when driving a car or other machinery

The drug does not affect the ability to drive or operate machinery. As with other ophthalmic drugs, short-term blurred vision may occur immediately after use, so you should wait for visual acuity to resume before driving or operating machinery.